Long-acting Injectable Medications (LAMs) Guidance Document and its Intersection With CCBHCs

Despite research-proven clinical benefits over oral medication, long-acting injectable medications (LAMs) are widely underutilized for people with psychotic, bipolar, alcohol use and opiate use disorders. LAMs’ benefits include a significant delay and reduction in relapse, particularly in patients with early-phase or first-episode schizophrenia, and a lower risk of discontinuation and frequency of hospitalizations than with oral antipsychotics, buprenorphine and naltrexone.  

We welcome medical directors and clinicians to join the National Council for Mental Wellbeing June 25, 1:30-2:30 p.m. ET, to explore recent data trends on the impact of LAMs. 

The webinar will cover topics including:  

• The current usage rates of LAMs.  
• The impact LAMs have on individuals with psychotic disorders.  
• Ways to expand the use of LAMs.